STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and moreSTAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where we have clear blue skies and chilly breezes greeting us today. Who could ask for anything more? Actually, we could — it is time to reheat the tea kettle for Read More
Novo Nordisk to halve U.S. list price of Wegovy from 2027Novo Nordisk to halve U.S. list price of Wegovy from 2027
Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Read More
Biden friends voice concern over increased fatigue amid cancer battle: reportBiden friends voice concern over increased fatigue amid cancer battle: report
Joe Biden continues radiation therapy for Stage 4 prostate cancer that has metastasized to bone, with aides saying the 83-year-old former president remains active and engaged.
Semaglutide may increase risk for nonarteritic anterior ischemic optic neuropathySemaglutide may increase risk for nonarteritic anterior ischemic optic neuropathy
People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2 inhibitors (SGLT2is), according to a brief report published online Feb. 12 in JAMA Ophthalmology. People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior Read More
STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding STAT+: In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding
In the last year and a half, direct-to-consumer telehealth company Hims & Hers has become a leading voice in the debate over compounded GLP-1 weight loss medications. On Monday, it announced earnings from the last quarter of 2025 after a whirlwind month that raised questions about the regulatory risks of the company’s compounding model and Read More
Bariatric Surgery and GLP-1 Drugs Both Support Sustained Fat LossBariatric Surgery and GLP-1 Drugs Both Support Sustained Fat Loss
Although bariatric surgery was associated with more evident changes, research found that treatment with glucagon-like peptide-1 (GLP-1) medications was also associated with sustained fat loss in a clinical setting. Although bariatric surgery was associated with more evident changes, research found that treatment with glucagon-like peptide-1 (GLP-1) medications was also associated with sustained fat loss in Read More
New GLP-1 Weight-Loss Drugs Expected This YearNew GLP-1 Weight-Loss Drugs Expected This Year
This Medical News article discusses clinical trial data for weight-loss medications, in both injectable and pill formations, that are currently under review with US Food and Drug Administration. This Medical News article discusses clinical trial data for weight-loss medications, in both injectable and pill formations, that are currently under review with US Food and Drug Read More
FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA MedicationsFDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications
The US Food and Drug Administration (FDA) requested that drug application holders remove suicidal ideation and behavior warnings from glucagon-like peptide-1 (GLP-1) receptor agonists. The US Food and Drug Administration (FDA) requested that drug application holders remove suicidal ideation and behavior warnings from glucagon-like peptide-1 (GLP-1) receptor agonists.
Study finds bariatric surgery outperforms medical therapy for T2D across income levelsStudy finds bariatric surgery outperforms medical therapy for T2D across income levels
Nonmedical factors drive up to 60 percent of health outcomes, and for people with type 2 diabetes (T2D), social determinants of health factors like poverty, food insecurity, and unstable housing can derail even the best treatment plans. Now, a long-term study led by investigators at Joslin Diabetes Center finds that bariatric metabolic surgery is more effective at glycemic and weight control than medical and lifestyle interventions for people with T2D, even in the setting of social vulnerability. The work is published in the journal Annals of Internal Medicine.
How the environment may affect breast cancer riskHow the environment may affect breast cancer risk
In the United States, breast cancer is the most common cancer diagnosed among women. In Texas, more than 22,000 women were expected to be diagnosed with breast cancer in 2025, according to the Texas Department of State Health Services.